Apocrine gland adenocarcinoma of the anal sac: Catch it early to improve prognosis
Dec 01, 2007
Although anal-sac tumors make up only 2 percent of all cutaneous neoplasms in dogs, they comprise a significant portion of the referrals to veterinary surgeons and oncologists.
Because of the large size of these tumors at the time of diagnosis and the early development of metastasis, the majority are found in more advanced stages, making successful treatment difficult. Treatment often is a multi-step process involving surgery, radiation therapy and chemotherapy. With aggressive treatment, even patients with advanced disease can experience prolonged control of these tumors with a good quality of life.
Mapping the clinical course
Metastasis to distant sites typically occurs in later stages of the disease.
The clinical course of anal-sac tumors can be insidious. The tumors can be an incidental finding during a routine examination. It is not uncommon for dogs referred to our clinic for another malignancy to be found with a previously undetected anal-sac mass. This underscores the importance of a rectal examination as part of a routine physical. Early detection will provide the best chance of achieving long-term control.
The slow progression of these tumors allows patients to adapt to enlarging tumors with few clinical signs. It is not until these tumors reach a critical volume that clinical signs develop.
Anal-sac tumors are the second most frequent malignant cause of hypercalcemia in dogs, next to lymphoma. The most effective method of controlling the hypercalcemia is by treatment of the primary tumor and/or metastatic disease. Dogs that present with hypercalcemia of an unknown origin, particularly older dogs, should have a thorough evaluation of the anal sacs, because even small tumors can cause significant hypercalcemia.
Hypercalemia can be found in up to 25 percent of dogs with anal-sac tumors (Moore, 2006). Not all dogs that are hypercalcemic will have clinical signs associated with hypercalcemia. Anal-sac tumors can produce a protein called PTH-rp (parathyroid hormone-related protein) that is capable of binding to PTH receptors, leading to alterations in calcium homeostasis and subsequent hypercalcemia and hypophosphotemia. PTH levels are low in these patients due to negative feedback.
Staging and diagnosis